---
title: "GSKADC therapy Phase 3 clinical results are positive, extending the lives of patients with refractory cancer"
description: "GSK announced today that its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) achieved positive results in the pre-specified interim analysis of the Phase 3 clinical trial DREAMM-7. The tr"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/219743914.md"
published_at: "2024-11-15T00:43:02.000Z"
---

# GSKADC therapy Phase 3 clinical results are positive, extending the lives of patients with refractory cancer

> GSK announced today that its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) achieved positive results in the pre-specified interim analysis of the Phase 3 clinical trial DREAMM-7. The trial evaluated the efficacy of Blenrep in combination with bortezomib and dexamethasone (BorDex) as a second-line or later treatment for relapsed or refractory multiple myeloma. The trial met the key secondary endpoint of overall survival (OS), demonstrating that Blenrep combined with BorDex significantly reduced the risk of death for patients compared to standard treatment regimens. The interim analysis results, including safety data, will be presented at the upcoming 66th American Society of Hematology (ASH) Annual Meeting. Blenrep is a targeted antibody-drug conjugate that targets B-cell maturation antigen (BCMA), consisting of a humanized anti-BCMA monoclonal antibody linked to the cytotoxic payload auristatin F via an indelible linker

According to Zhitong Finance APP, GSK (GSK.US) announced today that its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) achieved positive results in the pre-specified interim analysis of the Phase 3 clinical trial DREAMM-7. The trial evaluated the efficacy of Blenrep in combination with bortezomib and dexamethasone (BorDex) as a second-line or later treatment for relapsed or refractory multiple myeloma. The trial met the key secondary endpoint of overall survival (OS), showing that Blenrep combined with BorDex significantly reduced the risk of death for patients compared to standard treatment regimens. The interim analysis results, including safety data, will be presented at the upcoming 66th American Society of Hematology (ASH) Annual Meeting.

Blenrep is a targeted antibody-drug conjugate that targets B-cell maturation antigen (BCMA), composed of a humanized anti-BCMA monoclonal antibody linked to the cytotoxic payload auristatin F via an indelible linker

### Related Stocks

- [GSK.US - GSK](https://longbridge.com/en/quote/GSK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 葛蘭素史克啓動最多達 4.5 億英鎊的股票回購批次 | 葛蘭素史克啓動高達 4.5 億英鎊的股票回購計劃 | [Link](https://longbridge.com/en/news/276103252.md) |
| Exdensur 在歐盟獲批用於治療重度哮喘和慢性鼻竇炎伴鼻息肉（CRSwNP） | 葛蘭素史克已獲得歐洲委員會對 Exdensur（depemokimab）的批准，這是一種用於重度哮喘和伴有鼻息肉的慢性鼻竇炎的首個超長效生物製劑。該治療適用於 12 歲及以上的成年人和青少年，適用於那些在高劑量吸入類固醇治療下仍未得到有效控 | [Link](https://longbridge.com/en/news/276226507.md) |
| 特朗普陣營的堅定降息派動搖了？美聯儲理事米蘭：勞動力市場改善可令今年少些降息 | 堅定降息派、特朗普親信美聯儲理事米蘭：美國勞動力市場的改善可以令今年少些降息。風險提示及免責條款 市場有風險，投資需謹慎。本文不構成個人投資建議，也未考慮到個別用户特殊的投資目標、財務狀況或需要。用户應考慮本文中的任何意見、觀點或結論是否符 | [Link](https://longbridge.com/en/news/276386713.md) |
| 葛蘭素史克獲得歐洲委員會對 Exdensur 的批准 | 葛蘭素史克：葛蘭素史克 - 歐洲委員會批准的 EXDENSUR | [Link](https://longbridge.com/en/news/276102835.md) |
| GSK 的 Exdensur 在歐盟獲批用於重度哮喘和慢性鼻竇炎的附加治療 | GSK 的 Exdensur 在歐盟獲得批准，作為重度哮喘和慢性鼻竇炎的輔助治療 | [Link](https://longbridge.com/en/news/276103226.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
